Navigation Links
Hormonal male contraception reversible after few months for all men

With hormonal male contraception likely to be available in the near future, results of a study in this week's issue of THE LANCET highlight how such contraception is reversible within a few months.

Currently available male contraceptive methods (condoms, withdrawal, and vasectomy) are not acceptable to many couples because they are either not sufficiently reliable or not easily reversible. In a similar way to ovulation suppression by hormone treatment in women, sperm production can be fully inhibited by androgen or androgen-progestagen treatment combinations in men. With such hormone treatment, azoospermia (no sperm in ejaculate) or severe oligozoospermia (less than 3 million sperm per mL of semen), which is sufficient for contraceptive purposes, can be achieved. Currently, a large phase III study with an androgen treatment and a large, multicentre phase II study of androgen-progestagen combinations are being completed in China and Europe, respectively.

Peter Liu from the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed), who is currently located at the ANZAC Research Institute, University of Sydney, Australia, and colleagues analysed data from individual participants in 30 studies published in 1990?005, in which sperm output was monitored every month until recovery. The primary outcome was the time for the sperm concentration to recover to a threshold of 20 million per mL, an indicator of fertility.

Data were available for around 1500 men. The average time for sperm recovery to 20 million/mL was 3? months. Various factors were associated with higher rates of recovery including older age, Asian origin, shorter treatment duration, and higher sperm concentrations at baseline. Although these factors modulated the speed of recovery, spermatogenesis recovered to levels compatible with fertility in all men.

Dr Liu and colleagues comment: "Our data provide strong assurance that the previously described eff icacy of hormonal male contraceptives is coupled with highly predictable recovery to semen characteristics that are compatible with fertility. These findings thereby increase the promise of new contraceptive drugs allowing men to share more fairly the satisfaction and burden of family planning."


'"/>

Source:Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)


Related biology news :

1. Emergency contraception fails to halt abortions
2. Male contraception: One door opens, another closes
3. Cancer cells suppress large regions of DNA by a reversible process that can be tackled
4. Rewind, please: Nature paper shows that cell division is reversible
5. First-degree fetal heart block may be reversible
6. Mouse brain cells rapidly recover after Alzheimers plaques are cleared
7. Does vitamin C help prevent or treat the common cold? Maybe not, after all.
8. Stem cell treatment improves mobility after spinal cord injury
9. Bad aftertaste? New sensory on/off switch may cure bane of artificial sweetener search
10. New type of rejection blocker protects kidneys after transplant
11. Hurricane aftermath: Infectious disease threats from common, not exotic, diseases
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/30/2017)... , June 30, 2017 Today, ... developer and supplier of face and eye tracking ... Featured Product provider program. "Artificial ... innovative way to monitor a driver,s attentiveness levels ... from being able to detect fatigue and prevent ...
(Date:5/16/2017)... --  Bridge Patient Portal , an enterprise patient ... Systems , an electronic medical record solutions developer ... a partnership to build an interface between the ... products, including Centricity Practice Solution (CPS), Centricity Business ... integrations will allow healthcare delivery networks using GE ...
(Date:4/17/2017)... 2017 NXT-ID, Inc. (NASDAQ: NXTD ) ... of its 2016 Annual Report on Form 10-K on Thursday April ... ... in the Investor Relations section of the Company,s website at ... at http://www.sec.gov . 2016 Year Highlights: ...
Breaking Biology News(10 mins):
(Date:7/26/2017)... ... July 26, 2017 , ... ... the improvement of crop productivity and economics for the food, feed and biofuel ... of the agreement includes the research and development of microbiome-based seed treatments in ...
(Date:7/25/2017)... ... July 25, 2017 , ... ... Executive Director of Strategic Planning. His extensive background in consulting, development and ... experience encompasses marketing and differentiation consulting, business strategy development, new product marketing ...
(Date:7/24/2017)... BALTIMORE , July 24, 2017 Intralytix, ... equity funding from Lesaffre, a French family group. This ... both companies to develop and commercialize bacteriophage-based products, for ... of mutual interest. ... fermentation, Lesaffre designs manufactures and markets innovative solutions for ...
(Date:7/20/2017)... , ... July 20, 2017 , ... ... Fujimoto, Ph.D ., the Elihu Thomson Professor of Electrical Engineering and Computer Science ... Award winner. Presented annually, the award recognizes an individual who has made ...
Breaking Biology Technology: